Published in Antimicrob Agents Chemother on November 01, 1993
Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev (1998) 9.76
Resistance of Candida species to fluconazole. Antimicrob Agents Chemother (1995) 9.04
Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev (1995) 8.81
Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Antimicrob Agents Chemother (1995) 5.74
Selection of candidate quality control isolates and tentative quality control ranges for in vitro susceptibility testing of yeast isolates by National Committee for Clinical Laboratory Standards proposed standard methods. J Clin Microbiol (1994) 3.62
Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol (1994) 3.51
Comparative study of broth macrodilution and microdilution techniques for in vitro antifungal susceptibility testing of yeasts by using the National Committee for Clinical Laboratory Standards' proposed standard. J Clin Microbiol (1994) 2.81
In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob Agents Chemother (1997) 2.79
Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method. J Clin Microbiol (1998) 2.65
Susceptibility testing of fungi: current status of the standardization process. Antimicrob Agents Chemother (1993) 2.51
Cluster of oral atypical Candida albicans isolates in a group of human immunodeficiency virus-positive drug users. J Clin Microbiol (1995) 2.41
Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev (2006) 2.39
In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob Agents Chemother (2000) 2.33
Simple method for detecting fluconazole-resistant yeasts with chromogenic agar. J Clin Microbiol (1996) 2.28
Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome. J Clin Microbiol (1996) 2.19
Antifungal susceptibility testing of yeasts: evaluation of technical variables for test automation. Antimicrob Agents Chemother (1995) 2.07
In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Antimicrob Agents Chemother (1997) 2.00
In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob Agents Chemother (1994) 1.95
Susceptibility testing of Candida albicans and Aspergillus species by a simple microtiter menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay. J Clin Microbiol (1995) 1.94
Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole. Antimicrob Agents Chemother (2000) 1.57
Reversible fluconazole resistance in Candida albicans: a potential in vitro model. Antimicrob Agents Chemother (1997) 1.54
Fluconazole- and itraconazole-resistant Candida albicans strains from AIDS patients: multilocus enzyme electrophoresis analysis and antifungal susceptibilities. J Clin Microbiol (1995) 1.44
Immunosuppressive and nonimmunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin-dependent inhibition of calcineurin. Antimicrob Agents Chemother (2000) 1.42
Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrob Agents Chemother (1995) 1.40
In vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184. Antimicrob Agents Chemother (1995) 1.39
Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain. Antimicrob Agents Chemother (1995) 1.35
Structure-in vitro activity relationships of pentamidine analogues and dication-substituted bis-benzimidazoles as new antifungal agents. Antimicrob Agents Chemother (1998) 1.29
Variation in fluconazole efficacy for Candida albicans strains sequentially isolated from oral cavities of patients with AIDS in an experimental murine candidiasis model. Antimicrob Agents Chemother (1996) 1.28
The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. Antimicrob Agents Chemother (1997) 1.24
Azole resistance in Candida. Eur J Clin Microbiol Infect Dis (1997) 1.23
Antifungal prophylaxis during neutropenia and immunodeficiency. Clin Microbiol Rev (1997) 1.16
Fluconazole treatment of Candida albicans infection in mice: does in vitro susceptibility predict in vivo response? Antimicrob Agents Chemother (1995) 1.12
Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother (1994) 1.07
In vitro antifungal activities of a series of dication-substituted carbazoles, furans, and benzimidazoles. Antimicrob Agents Chemother (1998) 1.06
Comparative evaluation of three antifungal susceptibility test methods for Candida albicans isolates and correlation with response to fluconazole therapy. J Clin Microbiol (1996) 0.97
Fluconazole concentrations in saliva from AIDS patients with oropharyngeal candidosis refractory to treatment with fluconazole. Antimicrob Agents Chemother (1995) 0.96
Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection. HIV AIDS (Auckl) (2010) 0.92
Sensitive bioassay for determination of fluconazole concentrations in plasma using a Candida albicans mutant hypersusceptible to azoles. Antimicrob Agents Chemother (2001) 0.90
Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells. Antimicrob Agents Chemother (1999) 0.90
In vitro activity of a new polyene, SPA-S-843, against yeasts. Antimicrob Agents Chemother (1998) 0.89
Response to fluconazole by 23 patients with human immunodeficiency virus infection and oral candidiasis: pharmacological and mycological factors. Antimicrob Agents Chemother (1996) 0.86
In vitro and in vivo antifungal activities of TAK-456, a novel oral triazole with a broad antifungal spectrum. Antimicrob Agents Chemother (2002) 0.85
Evaluation by data mining techniques of fluconazole breakpoints established by the Clinical and Laboratory Standards Institute (CLSI) and comparison with those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Antimicrob Agents Chemother (2010) 0.81
Susceptibilities of Candida spp. to antifungal agents visualized by two-dimensional scatterplots of relative growth. Antimicrob Agents Chemother (1996) 0.80
In vitro activities and postantifungal effects of the potent dolastatin 10 derivative auristatin PHE. Antimicrob Agents Chemother (2001) 0.79
In Silico Design and Selection of Anti-fungal AmB-polyene-analog Lead Molecules by Virtual Screening Method. Avicenna J Med Biotechnol (2010) 0.75
Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol (1992) 12.13
Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med (1991) 12.09
Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrob Agents Chemother (1990) 8.42
Azole resistance in Candida albicans. Sabouraudia (1984) 6.23
A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med (1992) 6.06
Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model. J Infect Dis (1983) 4.42
Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits. Antimicrob Agents Chemother (1986) 3.38
Fluconazole resistant candida in AIDS. J Infect (1991) 2.97
In vitro susceptibilities and biotypes of Candida albicans isolates from the oral cavities of patients infected with human immunodeficiency virus. J Clin Microbiol (1988) 2.88
Development of resistance in candida isolates from patients receiving prolonged antifungal therapy. Antimicrob Agents Chemother (1991) 2.81
Candida albicans resistance in AIDS. J Infect (1991) 2.78
Fluconazole and Candida krusei fungemia. N Engl J Med (1991) 2.46
Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients. Am J Med (1983) 2.35
Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole. Eur J Clin Microbiol Infect Dis (1991) 2.08
Reduced azole susceptibility of oral isolates of Candida albicans from HIV-positive patients and a derivative exhibiting colony morphology variation. J Gen Microbiol (1992) 1.94
Fluconazole resistant candida in AIDS. J Infect (1991) 1.64
The identification and tracking of Candida albicans isolates from oral lesions in HIV-seropositive individuals. J Acquir Immune Defic Syndr (1992) 1.62
Prophylactic oral fluconazole and candida fungaemia. Lancet (1991) 1.33
Mucosal candidiasis caused by non-albicans species of Candida in HIV-positive patients. AIDS (1992) 1.29
[Resistance to fluconazole in hospitalized patients. Concordance between Candida albicans resistance in vitro and therapeutic failure]. Presse Med (1991) 1.24
Persistence of the same Candida albicans strain despite fluconazole therapy. Documentation by pulsed-field gel electrophoresis. Diagn Microbiol Infect Dis (1992) 1.08
Fluconazole prophylaxis of recurrent oral candidiasis in HIV-positive patients. Eur J Clin Microbiol Infect Dis (1991) 1.06
Prophylactic fluconazole and Candida krusei infections. N Engl J Med (1992) 1.01
Characterization of the mycoflora from oral mucosal surfaces of some HIV-infected patients. Oral Surg Oral Med Oral Pathol (1990) 0.99
Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev (1995) 8.81
Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.53
Gene transfer in Cryptococcus neoformans by use of biolistic delivery of DNA. J Bacteriol (1993) 5.14
Extra-intestinal manifestations of salmonella infections. Medicine (Baltimore) (1987) 4.77
Chronic cryptococcal meningitis: a new experimental model in rabbits. Am J Pathol (1980) 4.28
Cryptococcus neoformans mating and virulence are regulated by the G-protein alpha subunit GPA1 and cAMP. Genes Dev (1997) 4.28
Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis (2001) 4.01
Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide. J Clin Invest (1985) 3.98
Effect of the laccase gene CNLAC1, on virulence of Cryptococcus neoformans. J Exp Med (1996) 3.76
Specific amino acid (L-arginine) requirement for the microbiostatic activity of murine macrophages. J Clin Invest (1988) 3.69
Urease as a virulence factor in experimental cryptococcosis. Infect Immun (2000) 3.53
Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits. Antimicrob Agents Chemother (1986) 3.38
In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother (1996) 3.20
Cyclic AMP-dependent protein kinase controls virulence of the fungal pathogen Cryptococcus neoformans. Mol Cell Biol (2001) 3.11
Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis (1998) 3.09
Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans. Mol Microbiol (2001) 3.02
Metabolic fate of L-arginine in relation to microbiostatic capability of murine macrophages. J Clin Invest (1990) 2.91
Infection due to Actinobacillus actinomycetemcomitans: 15 cases and review. Rev Infect Dis (1989) 2.89
In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob Agents Chemother (1997) 2.76
Facing the challenge of HIV. Primary care physicians have an obligation to care for those infected. N C Med J (1994) 2.69
Morphologic criteria for the preliminary identification of Fusarium, Paecilomyces, and Acremonium species by histopathology. Am J Clin Pathol (1998) 2.30
RAS1 regulates filamentation, mating and growth at high temperature of Cryptococcus neoformans. Mol Microbiol (2000) 2.30
Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis (2006) 2.17
The new fungal opportunists are coming. Clin Infect Dis (1996) 2.10
Cryptococcemia. Medicine (Baltimore) (1983) 2.10
Macrophage-mediated fungistasis in vitro: requirements for intracellular and extracellular cytotoxicity. J Immunol (1986) 2.06
The G-protein beta subunit GPB1 is required for mating and haploid fruiting in Cryptococcus neoformans. Mol Cell Biol (2000) 2.03
Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. J Antimicrob Chemother (1985) 2.02
Identification of the MATa mating-type locus of Cryptococcus neoformans reveals a serotype A MATa strain thought to have been extinct. Proc Natl Acad Sci U S A (2000) 1.96
Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci U S A (2001) 1.89
Effects of antifungal agents and gamma interferon on macrophage cytotoxicity for fungi and tumor cells. J Infect Dis (1987) 1.85
Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother (1994) 1.79
Comparison of amphotericin B and N-D-ornithyl amphotericin B methyl ester in experimental cryptococcal meningitis and Candida albicans endocarditis with pyelonephritis. Antimicrob Agents Chemother (1985) 1.78
Identification and characterization of a highly conserved calcineurin binding protein, CBP1/calcipressin, in Cryptococcus neoformans. EMBO J (2000) 1.76
The STE12alpha homolog is required for haploid filamentation but largely dispensable for mating and virulence in Cryptococcus neoformans. Genetics (1999) 1.75
Epidemic giardiasis caused by a contaminated public water supply. Am J Public Health (1988) 1.72
Targeted gene replacement demonstrates that myristoyl-CoA: protein N-myristoyltransferase is essential for viability of Cryptococcus neoformans. Proc Natl Acad Sci U S A (1994) 1.72
Roles for inositol-phosphoryl ceramide synthase 1 (IPC1) in pathogenesis of C. neoformans. Genes Dev (2001) 1.72
Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob Agents Chemother (2000) 1.66
CD8+ T lymphocyte-mediated inhibition of HIV-1 long terminal repeat transcription: a novel antiviral mechanism. AIDS Res Hum Retroviruses (1993) 1.66
Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob Agents Chemother (1996) 1.65
A glucan synthase FKS1 homolog in cryptococcus neoformans is single copy and encodes an essential function. J Bacteriol (1999) 1.65
Rapamycin antifungal action is mediated via conserved complexes with FKBP12 and TOR kinase homologs in Cryptococcus neoformans. Mol Cell Biol (1999) 1.64
Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches. Drugs (1997) 1.63
HIV-associated autoimmune hemolytic anemia: report of a case and review of the literature. J Acquir Immune Defic Syndr (1990) 1.63
Treatment of experimental cryptococcal meningitis with amphotericin B, 5-fluorocytosine, and ketoconazole. J Infect Dis (1982) 1.58
Fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Ann Intern Med (1983) 1.56
HIV-relevant sexual behavior among a healthy inner-city heterosexual adolescent population in an endemic area of HIV. J Adolesc Health (1991) 1.55
Dominant selection system for use in Cryptococcus neoformans. J Med Vet Mycol (1997) 1.54
Amplification of HIV-1 provirus from cerebrospinal fluid and its correlation with neurologic disease. J Infect Dis (1990) 1.54
Sociodemographic and clinical characteristics of clients presenting for HIV voluntary counselling and testing in Moshi, Tanzania. Int J STD AIDS (2005) 1.53
Association of plasma levels of human immunodeficiency virus type 1 RNA and oropharyngeal Candida colonization. J Infect Dis (1999) 1.51
Fungal meningitis. Semin Neurol (2000) 1.50
Cryptococcus neoformans gene expression during experimental cryptococcal meningitis. Eukaryot Cell (2003) 1.49
FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med (1993) 1.47
Two cyclophilin A homologs with shared and distinct functions important for growth and virulence of Cryptococcus neoformans. EMBO Rep (2001) 1.46
Disseminated zygomycosis: report of four cases and review. Rev Infect Dis (1989) 1.45
Immunosuppressive and nonimmunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin-dependent inhibition of calcineurin. Antimicrob Agents Chemother (2000) 1.42
Aerosol pentamidine prophylaxis following Pneumocystis carinii pneumonia in AIDS patients: results of a blinded dose-comparison study using an ultrasonic nebulizer. Am J Med (1991) 1.41
Signal transduction pathways regulating differentiation and pathogenicity of Cryptococcus neoformans. Fungal Genet Biol (1998) 1.41
The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA (1994) 1.41
Giardia transmission in a swimming pool. Am J Public Health (1988) 1.39
Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR. Antimicrob Agents Chemother (2001) 1.37
The sequences of reovirus serotype 3 genome segments M1 and M3 encoding the minor protein mu 2 and the major nonstructural protein mu NS, respectively. Virology (1989) 1.31
Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis. Rev Infect Dis (1985) 1.31
Structure-in vitro activity relationships of pentamidine analogues and dication-substituted bis-benzimidazoles as new antifungal agents. Antimicrob Agents Chemother (1998) 1.29
Influence of agglutinating antibody in experimental cryptococcal meningitis. Br J Exp Pathol (1981) 1.29
HIV-associated morbidity, mortality and diagnostic testing opportunities among inpatients at a referral hospital in northern Tanzania. Ann Trop Med Parasitol (2004) 1.29
Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother (2012) 1.28
Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother (1987) 1.27
Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials. Antimicrob Agents Chemother (1999) 1.25
Diguanidino and "reversed" diamidino 2,5-diarylfurans as antimicrobial agents. J Med Chem (2001) 1.25
Scedosporium species infections and treatments. J Chemother (2003) 1.23
Production of the hexitol D-mannitol by Cryptococcus neoformans in vitro and in rabbits with experimental meningitis. Infect Immun (1990) 1.23
Cryptococcus neoformans differential gene expression detected in vitro and in vivo with green fluorescent protein. Infect Immun (1999) 1.22
Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action. Clin Microbiol Rev (1999) 1.21
The actin gene from Cryptococcus neoformans: structure and phylogenetic analysis. J Med Vet Mycol (1996) 1.21
Formation of azole-resistant Candida albicans by mutation of sterol 14-demethylase P450. Antimicrob Agents Chemother (1999) 1.21
Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects. J Immunol (1990) 1.21
Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease. Eur J Clin Microbiol Infect Dis (2008) 1.20
Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective, multicenter trial. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 1.20
Effects of cyclosporine in experimental cryptococcal meningitis. Infect Immun (1985) 1.19
Analysis of the adult thymus in reconstitution of T lymphocytes in HIV-1 infection. J Clin Invest (1999) 1.19
Prevalence of antibody to Trypanosoma cruzi among blood donors in Los Angeles, California. Transfusion (1992) 1.16
Identification and characterization of an SKN7 homologue in Cryptococcus neoformans. Infect Immun (2005) 1.16
Identification and characterization of the Cryptococcus neoformans phosphomannose isomerase-encoding gene, MAN1, and its impact on pathogenicity. Mol Microbiol (2001) 1.15
Topoisomerase I is essential in Cryptococcus neoformans: role In pathobiology and as an antifungal target. Genetics (1999) 1.15
Fusarium infection in burned patients. Am J Clin Pathol (1981) 1.13
The isolation of FOS-1, a gene encoding a putative two-component histidine kinase from Aspergillus fumigatus. Fungal Genet Biol (2000) 1.13
Macrophage-mediated fungistasis: requirement for a macromolecular component in serum. J Immunol (1986) 1.12
Treatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother (2000) 1.12
The pharmacokinetics of BAY R3783 and its efficacy in the treatment of experimental cryptococcal meningitis. J Antimicrob Chemother (1990) 1.12
Manifestations of pulmonary cryptococcosis in patients with acquired immunodeficiency syndrome. Rev Infect Dis (1991) 1.11
Fungal scleritis after cataract surgery. Successful outcome using itraconazole. Cornea (1992) 1.11